ArticleJournal of translational medicine2025
Translational deep learning models for risk stratification to predict prognosis and immunotherapy response in gastric cancer using digital pathology.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal AI and single-cell transcriptomics integrate to construct a histopathological prognostic model for bladder cancer, revealing the RTN3-glycolysis axis in chemoresistance.Experimental hematology & oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is one of the leading causes of cancer-related deaths globally, with a 5-year survival rate of less than 40%. While immune checkpoint inhibitors have provided promising therapeutic options for advanced GC, only a small proportion of patients benefit. In this study, we developed a deep learning model using whole-slide images to predict prognoses and sensitivity to immune checkpoint inhibitors in GC patients by predicting a novel marker.
methodsFormalin-fixed, paraffin-embedded whole-slide images from 292 patients in the Cancer Genome Atlas-Stomach Adenocarcinoma cohort were analyzed. Tumor regions were identified using a ResNet50-based tumor detection model and validated in HiESD dataset. Tiles classified as malignant were extracted for subsequent analysis. Risk score prediction models were developed using convolutional neural networks, clustering-constrained attention multiple-instance learning (CLAM), and dual-stream multiple-instance learning (DSMIL). Attention heatmap visualization was used to interpret tumor microenvironment (TME) features and a multi-model classification framework utilizing a support vector machine (SVM) was developed to assess the impact of clinical variables in model performances. The results were evaluated using the area under the receiver operating characteristic curve (AUROC), accuracy, sensitivity, specificity, and F1 score.
resultsThe tumor detection model achieved an AUROC of 0.99 on the training set, 0.92 on the test set, and 0.87 on external test set. Among risk score prediction models, DSMIL demonstrated the highest performance, with an AUROC of 0.73 and accuracy of 0.73 on the training set and AUROC of 0.70 and accuracy of 0.68 on the internal test set. High-risk patients exhibited worse survival outcomes and lower immunotherapy response rates compared with low-risk patients. Feature attribution analysis using attention heatmaps confirmed that the model prioritized TME components, specifically regions with dense lymphocytic infiltration. The muti-modal analysis showed that the image features alone were superior to the model combining image features with clinicopathological data.
conclusionDeep learning models leveraging whole-slide images show potential in predicting prognoses and immunotherapy responses in GC. By integrating tumor-specific and tumor microenvironmental features, this approach offers a scalable, objective tool for personalized treatment planning, improving precision oncology strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.